Continuous Glucose Monitoring Stocks
Medical technology firms in this vertical develop and commercialize wearable sensor systems designed for real-time tracking of interstitial glucose levels, shifting diabetes management from episodic finger-stick testing to automated data streams. Revenue models center on high-margin recurring disposables and integrated software subscriptions, often tethered to automated insulin delivery hardware.
As of Oct 23, 2026, Continuous Glucose Monitoring has 9 US-listed companies worth $214B combined. The median member moved -2.2% over the past week; TNDM led at +7.3% and GCTK trailed at -44.4%.
Companies in Continuous Glucose Monitoring
- ABT – Abbott Laboratories, $177B
- DXCM – DexCom Inc, $29.6B
- MMED – MiniMed Group, Inc. Common Stock, $5.2B
- TNDM – Tandem Diabetes Care Inc, $1.1B
- SENS – Senseonics Holdings, Inc. Common Stock, $484M
- MOVE – Movano Inc, $276M
- ACH – Accendra Health Inc, $19.6M
- GCTK – GlucoTrack Inc, $662,830
- NMRD – Nemaura Medical Inc, $4,035